Himalaya Nutravedics India Ltd
Incorporated in June 2022, Himalaya Nutravedics India Limited is engaged
in the manufacturing, marketing, and
distribution of Ayurvedic and nutraceutical formulations.[1]
- Market Cap ₹ 108 Cr.
- Current Price ₹ 123
- High / Low ₹ 124 / 111
- Stock P/E 14.6
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 52.2 %
- ROE 63.9 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 59.8%
Cons
- Working capital days have increased from 69.7 days to 105 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 2.05 | 14.43 | 21.00 | 43.06 | |
| 1.77 | 13.49 | 18.01 | 34.95 | |
| Operating Profit | 0.28 | 0.94 | 2.99 | 8.11 |
| OPM % | 13.66% | 6.51% | 14.24% | 18.83% |
| 0.00 | 0.00 | 0.00 | 0.05 | |
| Interest | 0.02 | 0.18 | 0.32 | 0.35 |
| Depreciation | 0.06 | 0.16 | 0.42 | 0.33 |
| Profit before tax | 0.20 | 0.60 | 2.25 | 7.48 |
| Tax % | 25.00% | 28.33% | 0.89% | 1.20% |
| 0.15 | 0.43 | 2.23 | 7.39 | |
| EPS in Rs | 1.81 | 5.18 | 5.58 | 11.72 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 176% |
| TTM: | 105% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 267% |
| TTM: | 231% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 60% |
| Last Year: | 64% |
Balance Sheet
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.83 | 0.83 | 4.00 | 6.31 |
| Reserves | 0.15 | 0.53 | 2.76 | 10.07 |
| 1.32 | 3.24 | 1.76 | 5.13 | |
| 0.93 | 1.49 | 2.30 | 2.91 | |
| Total Liabilities | 3.23 | 6.09 | 10.82 | 24.42 |
| 0.58 | 1.50 | 1.29 | 1.03 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.02 | 0.03 | 0.07 |
| 2.65 | 4.57 | 9.50 | 23.32 | |
| Total Assets | 3.23 | 6.09 | 10.82 | 24.42 |
Cash Flows
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| -0.55 | -1.39 | -3.83 | ||
| -1.10 | -0.23 | -0.06 | ||
| 1.84 | 1.44 | 5.27 | ||
| Net Cash Flow | 0.19 | -0.18 | 1.38 | |
| Free Cash Flow | -1.63 | -1.60 | -3.90 | |
| CFO/OP | -40% | -46% | -46% |
Ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 169.15 | 39.21 | 98.03 | 89.77 |
| Inventory Days | 735.53 | 112.03 | 96.55 | 142.67 |
| Days Payable | 60.83 | 27.56 | 37.68 | 11.20 |
| Cash Conversion Cycle | 843.84 | 123.68 | 156.90 | 221.24 |
| Working Capital Days | 295.56 | 6.58 | 97.85 | 104.69 |
| ROCE % | 22.61% | 39.18% | 52.15% |
Business Overview[1]
Himalaya Nutravedics India manufactures, markets, and distributes Ayurvedic and Nutraceutical formulations in India. The
company also undertakes third-party
contract manufacturing for other Ayurvedic
and nutraceutical companies. Its portfolio
spans classical Ayurvedic formulations, proprietary Ayurvedic formulations and nutraceutical supplements across multiple dosage forms.